The Food and Drug Administration warned that patients using AbbVie Inc.'s (NYSE: ABBV) hepatitis C treatments Viekira Pak and Technivie are at a higher risk of serious liver injury. The stock price plunged $5.56 to close at $48.27. Shares of Encanta Pharmaceuticals Inc. (Nasdaq: ENTA), which helped develop some of AbbVie's treatments, plummeted $16.35 to close at $23.90 on the FDA warning.
FDA warns about AbbVie drug side effects
October 22, 2015 at 19:49 PM EDT
